137 related articles for article (PubMed ID: 38373426)
1. Denosumab in the treatment of osteoporosis associated with chronic kidney disease.
Covic A; Apetrii M
Lancet Diabetes Endocrinol; 2024 Apr; 12(4):225-227. PubMed ID: 38373426
[No Abstract] [Full Text] [Related]
2. The effect of previous treatment with bisphosphonate and renal impairment on the response to denosumab in osteoporosis: a 'real-life' study.
Fraser TR; Flogaitis I; Moore AE; Hampson G
J Endocrinol Invest; 2020 Apr; 43(4):469-475. PubMed ID: 31664706
[TBL] [Abstract][Full Text] [Related]
3. Fracture risk and treatment in chronic kidney disease.
Connelly K; Collister D; Tangri N
Curr Opin Nephrol Hypertens; 2018 May; 27(3):221-225. PubMed ID: 29547405
[TBL] [Abstract][Full Text] [Related]
4. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.
Bover J; Bailone L; López-Báez V; Benito S; Ciceri P; Galassi A; Cozzolino M
J Nephrol; 2017 Oct; 30(5):677-687. PubMed ID: 28432640
[TBL] [Abstract][Full Text] [Related]
5. Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency.
Miyaoka D; Imanishi Y; Ohara M; Hayashi N; Nagata Y; Yamada S; Mori K; Emoto M; Inaba M
Osteoporos Int; 2019 Jan; 30(1):241-249. PubMed ID: 30187112
[TBL] [Abstract][Full Text] [Related]
6. Denosumab for osteoporosis in patients with primary hyperparathyroidism and mild-to-moderate renal insufficiency.
Gronskaya S; Belaya Z; Rozhinskaya L; Mamedova E; Vorontsova M; Solodovnikov A; Golounina O; Melnichenko G
Endocrine; 2023 Aug; 81(2):368-378. PubMed ID: 37133642
[TBL] [Abstract][Full Text] [Related]
7. Treating Osteoporosis with Denosumab in Patients on Hemodialysis: The Good, the Bad, and the Ugly.
Nickolas TL
Clin J Am Soc Nephrol; 2023 Sep; 18(9):1116-1118. PubMed ID: 37533153
[No Abstract] [Full Text] [Related]
8. [Osteoporosis treatment for patients with chronic kidney disease].
Konishi Y
Nihon Rinsho; 2015 Oct; 73(10):1723-7. PubMed ID: 26529937
[TBL] [Abstract][Full Text] [Related]
9. Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis.
Wilson LM; Rebholz CM; Jirru E; Liu MC; Zhang A; Gayleard J; Chu Y; Robinson KA
Ann Intern Med; 2017 May; 166(9):649-658. PubMed ID: 28395318
[TBL] [Abstract][Full Text] [Related]
10. Bone Histomorphometry in an Osteoporotic Hemodialysis Patient Treated With Denosumab.
Ibuki Y; Hukuda T; Tabata S; Ito A
Ther Apher Dial; 2018 Jun; 22(3):302-304. PubMed ID: 28594111
[No Abstract] [Full Text] [Related]
11. [Osteoporosis and chronic kidney disease: review and new therapeutic strategies].
Sessa C; Galeano D; Alessandrello I; Aprile G; Distefano G; Ficara V; Giglio E; Musumeci S; Pocorobba B; Zuppardo C; Musso S; Granata A
G Ital Nefrol; 2019 Jul; 36(4):. PubMed ID: 31373465
[TBL] [Abstract][Full Text] [Related]
12. Denosumab for dialysis patients with osteoporosis: A cohort study.
Kunizawa K; Hiramatsu R; Hoshino J; Mizuno H; Ozawa Y; Sekine A; Kawada M; Sumida K; Hasegawa E; Yamanouchi M; Hayami N; Suwabe T; Sawa N; Ubara Y; Takaichi K
Sci Rep; 2020 Feb; 10(1):2496. PubMed ID: 32051451
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of osteoporosis with denosumab: it is necessary to anticipate its eventual discontinuation].
Roux C
Rev Prat; 2019 Jun; 69(6):592-594. PubMed ID: 31626412
[No Abstract] [Full Text] [Related]
14. Life-threatening hypocalcaemia associated with denosumab in advanced chronic kidney disease.
Killen JP; Yong K; Luxton G; Endre Z
Intern Med J; 2016 Jun; 46(6):746-7. PubMed ID: 27257154
[No Abstract] [Full Text] [Related]
15. Clinical vertebral fractures following denosumab discontinuation.
Polyzos SA; Terpos E
Endocrine; 2016 Oct; 54(1):271-272. PubMed ID: 27393301
[No Abstract] [Full Text] [Related]
16. Efficacy of denosumab therapy after alendronate treatment for a 66-year-old woman with Camurati-Engelmann disease and osteoporosis: a case report.
Uehara M; Nakamura Y; Suzuki T; Takahashi J; Kato H
Mod Rheumatol Case Rep; 2020 Jan; 4(1):131-134. PubMed ID: 33086975
[TBL] [Abstract][Full Text] [Related]
17. Hypercalcaemia-induced acute kidney injury in an older patient with osteoporosis treated with alfacalcidol for denosumab-induced hypocalcaemia.
Yamada S; Matsuo M; Tokumoto M; Ooboshi H
Nephrology (Carlton); 2017 Jul; 22(7):572-573. PubMed ID: 28621008
[No Abstract] [Full Text] [Related]
18. Denosumab for the Treatment of Mastocytosis-Related Osteoporosis: A Case Series.
Orsolini G; Gavioli I; Tripi G; Viapiana O; Gatti D; Idolazzi L; Zanotti R; Rossini M
Calcif Tissue Int; 2017 Jun; 100(6):595-598. PubMed ID: 28229176
[TBL] [Abstract][Full Text] [Related]
19. Denosumab-related hypocalcaemia in chronic kidney disease.
Yong CH
Aust J Gen Pract; 2018 Aug; 47(8):538-539. PubMed ID: 30114884
[No Abstract] [Full Text] [Related]
20. Safety and efficacy of denosumab in osteoporotic hemodialysed patients.
Festuccia F; Jafari MT; Moioli A; Fofi C; Barberi S; Amendola S; Sciacchitano S; Punzo G; Menè P
J Nephrol; 2017 Apr; 30(2):271-279. PubMed ID: 27394428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
